ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX ...

Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the ...

Scientists have developed a universal kidney transplant by converting a donor kidney to blood type O, enabling compatibility with any recipient.

Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...

Tubulis has completed a Series C, securing €308m ($361m) to be directed towards advancing clinical development of its ADC ...

Abstract: Chronic Kidney Disease (CKD) has become a serious public health problem because of its characteristic ’three highs and one low’: high prevalence, high disability rate, high medical costs, ...